Clinical Oncology
Volume 22, Issue 3 , Pages 231-235 , April 2010

Life after First-line Chemotherapy in Malignant Pleural Mesothelioma: a North-East England Experience

  • J. Steer

      Affiliations

    • Department of Respiratory Medicine, Sunderland Royal Hospital, Sunderland, UK
    • ,
  • G. Bough

      Affiliations

    • Northern Centre for Cancer Care, Newcastle Hospitals Foundation Trust, Freeman Hospital, Newcastle upon Tyne, UK
    • ,
  • A.R.A. Razak

      Affiliations

    • Northern Centre for Cancer Care, Newcastle Hospitals Foundation Trust, Freeman Hospital, Newcastle upon Tyne, UK
    • Northern Institute for Cancer Research, Medical School, Newcastle University, Newcastle, UK
    • Corresponding Author InformationAuthor for correspondence: A.R.A. Razak, Drug Development Unit, Princess Margaret Hospital, 7-702, 620 University Avenue, Toronto, Ontario M5G 2M9, Canada. Tel: +1-416-500-4011.
    • ,
  • G.J. Meachery

      Affiliations

    • Department of Respiratory Medicine, Sunderland Royal Hospital, Sunderland, UK
    • ,
  • A. Hughes

      Affiliations

    • Northern Centre for Cancer Care, Newcastle Hospitals Foundation Trust, Freeman Hospital, Newcastle upon Tyne, UK

Received 9 September 2009 ,Revised 30 December 2009 ,Accepted 29 January 2010.

References 

  1. Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med. 1960;17:260–271
  2. Bianchi C, Giarelli L, Grandi G, Brollo A, Ramani L, Zuch C. Latency periods in asbestos-related mesothelioma of the pleura. Eur J Cancer Prev. 1997;6:162–166
  3. Kindler HL. Systemic treatments for mesothelioma: standard and novel. Curr Treat Options Oncol. 2008;9:171–179
  4. van Meerbeeck JP, Gaafar R, Manegold C, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol. 2005;23:6881–6889
  5. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636–2644
  6. Jassem J, Ramlau R, Santoro A, et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol. 2008;26:1698–1704
  7. Manegold C, Symanowski J, Gatzemeier U, et al. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol. 2005;16:923–927
  8. Razak AR, Chatten KJ, Hughes AN. Retreatment with pemetrexed-based chemotherapy in malignant pleural mesothelioma (MPM): a second line treatment option. Lung Cancer. 2008;60:294–297
  9. Hughes A, Calvert P, Azzabi A, et al. Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J Clin Oncol. 2002;20:3533–3544
  10. O'Rourke N, Garcia JC, Paul J, Lawless C, McMenemin R, Hill J. A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma. Radiother Oncol. 2007;84:18–22

PII: S0936-6555(10)00046-4

doi: 10.1016/j.clon.2010.01.009

Clinical Oncology
Volume 22, Issue 3 , Pages 231-235 , April 2010

Article Tools

* Image Usage & Resolution